Want to see TSE:APS full AI Analyst Report?

Aptose Biosciences (APS) Price & Analysis

146 Followers

APS Stock Chart & Stats

C$2.16

-C$0.01(-3.08%)

At close: Jan 08 4:00 PM EST

C$2.16

-C$0.01(-3.08%)

Day’s Range― - ―

52-Week RangeC$1.11 - C$2.59

Previous CloseN/A

Volume48.76K

Average Volume (3M)3.35K

Market Cap

C$5.46M

Enterprise ValueC$3.42M

Total Cash (Recent Filing)C$4.11M

Total Debt (Recent Filing)C$34.26M

Price to Earnings (P/E)―

Beta-1.09

Next Earnings

Aug 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.80

Shares Outstanding2,552,429

10 Day Avg. Volume4,664

30 Day Avg. Volume3,346

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.14

Price to Sales (P/S)0.00

P/FCF Ratio-0.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-5.65

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTuspetinib is a highly differentiated kinase inhibitor with favorable safety and broad activity across difficult-to-treat AML subpopulations, including those with TP53, RAS, and FLT3 mutations.

Financial CollaborationAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Bears Say

Cash ReservesThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Aptose Biosciences News

Hanmi Completes Acquisition, Taking Aptose Biosciences Private

Aptose Biosciences ( ($TSE:APS) ) has provided an update. On June 30, 2026, Aptose Biosciences announced the closing...

17h ago

Aptose Biosciences Acquired by Hanmi, Plans Delisting

An update from Aptose Biosciences ( ($TSE:APS) ) is now available. On June 30, 2026, Aptose Biosciences completed...

17h ago

Aptose Highlights Promising TUSCANY Triplet Data in AML

Aptose Biosciences ( ($TSE:APS) ) has issued an update. On June 15, 2026, Aptose Biosciences reported new clinical...

17d ago

Aptose Biosciences Updates Hanmi Acquisition Timeline and Financing

Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. On May 29, 2026, Aptose Biosciences said closing of...

1M ago

Aptose Hanmi Acquisition Closing Delayed Pending Korean Approvals

An announcement from Aptose Biosciences ( ($TSE:APS) ) is now available. Aptose Biosciences Inc., a clinical-stage biotech developer...

2M ago

Aptose Shareholders Approve Hanmi Go‑Private Acquisition Plan

Aptose Biosciences ( ($TSE:APS) ) has shared an update. On March 31, 2026, Aptose Biosciences reported that shareholders...

3M ago

Aptose Shareholders Approve Hanmi Acquisition and Re-Domiciling

Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. On March 31, 2026, Aptose Biosciences Inc. shareholders approved...

3M ago

Aptose Clarifies CEO Employment Terms and Compensation Obligations

The latest announcement is out from Aptose Biosciences ( ($TSE:APS) ). On March 12, 2026, Aptose Biosciences Inc....

3M ago

Glass Lewis Backs Aptose Hanmi Acquisition Arrangement Plan

Aptose Biosciences ( ($TSE:APS) ) has provided an update. Aptose Biosciences, a clinical-stage oncology biotech focused on precision...

3M ago

ISS Backs Hanmi’s Cash Takeover of Aptose Ahead of March 31 Vote

Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Biosciences said proxy adviser Institutional Shareholder Services has...

3M ago

Aptose Biosciences says ISS recommends shareholders vote for Hanmi arrangement

Aptose Biosciences (APTOF) announced that Institutional Shareholder Services has recommended that Aptose shareholders vote “FOR” a special resolution...

3M ago

Aptose Biosciences announces amendment to arrangement agreement

Aptose Biosciences (APTOF) entered into an amended and restated arrangement agreement dated February 23, 2026 amending and restating...

4M ago

Aptose Biosciences downgraded to Neutral from Buy at Alliance Global

Alliance Global downgraded Aptose Biosciences (APTOF) to Neutral from Buy with a C$2.41 price target The firm does...

7M ago

Aptose Biosciences shares to delist from Nasdaq as of April 2

Aptose Biosciences (APTO) announced that the Nasdaq Hearings Panel has determined to delist the common shares of the...

1y ago

APTO

APS FAQ

What was Aptose Biosciences’s price range in the past 12 months?

Aptose Biosciences lowest stock price was C$1.11 and its highest was C$2.59 in the past 12 months.

What is Aptose Biosciences’s market cap?

Aptose Biosciences’s market cap is C$5.46M.

When is Aptose Biosciences’s upcoming earnings report date?

Aptose Biosciences’s upcoming earnings report date is Aug 04, 2026 which is in 33 days.

How were Aptose Biosciences’s earnings last quarter?

Currently, no data Available

Is Aptose Biosciences overvalued?

According to Wall Street analysts Aptose Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aptose Biosciences pay dividends?

Aptose Biosciences does not currently pay dividends.

What is Aptose Biosciences’s EPS estimate?

Aptose Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aptose Biosciences have?

Aptose Biosciences has 2,552,429 shares outstanding.

What happened to Aptose Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aptose Biosciences?

Currently, no hedge funds are holding shares in TSE:APS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aptose Biosciences

Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.